Article Details

ACTG announces results from investigational inhaled COVID-19 treatment in ACTIV-2 phase 2 study

Retrieved on: 2022-10-05 02:11:06

Tags for this article:

Click the tags to see associated articles and topics

ACTG announces results from investigational inhaled COVID-19 treatment in ACTIV-2 phase 2 study. View article details on hiswai:

Excerpt

... inhaled formulation of interferon beta, with placebo in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

Article found on: www.eurekalert.org

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up